Advertisement
UK markets open in 2 hours 29 minutes

  • NIKKEI 225

    37,673.53
    -786.55 (-2.05%)
     

  • HANG SENG

    17,295.93
    +94.66 (+0.55%)
     

  • CRUDE OIL

    82.88
    +0.07 (+0.08%)
     

  • GOLD FUTURES

    2,325.60
    -12.80 (-0.55%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • Bitcoin GBP

    51,479.18
    -2,076.39 (-3.88%)
     

  • CMC Crypto 200

    1,384.35
    -39.75 (-2.79%)
     

  • NASDAQ Composite

    15,712.75
    +16.11 (+0.10%)
     

  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     
Money:

The five essential pieces of financial paperwork you must never lose

Mislaying key documents can cause real headaches, so it’s worth tracking down these most commonly-lost bits of paperwork

AstraZeneca's Farxiga meets main goal of heart failure study

Reuters - UK Focus

Aug 20 (Reuters) - British drugmaker AstraZeneca Plc said on Tuesday that its diabetes drug Farxiga met the main goal of a late-stage study for the treatment of patients with heart failure.

Farxiga was successful in reducing the risk of cardiovascular death or the worsening of heart failure when used along with the standard treatment in the DAPA-HF trial, the company said in a statement. (Reporting by Pushkala Aripaka in Bengaluru; editing by Patrick Graham)